Profil bibliographique

Matteo Dugo

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

222Publications signalées

3804Citations signalées

4Affiliations récentes

Institutions déclarées

Vita-Salute San Raffaele University IRCCS Ospedale San Raffaele Istituti di Ricovero e Cura a Carattere Scientifico Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele

Domaines associés

Cancer Immunotherapy and BiomarkersAdvanced Breast Cancer TherapiesEstrogen and related hormone effectsBreast Cancer Treatment StudiesHER2/EGFR in Cancer Research

Publications récentes

Accès ouvert 2026 preprint

ENPP3 expressed by HER2-positive breast cancer cells is associated with good prognosis by restraining epithelial-to-mesenchymal phenotype

Roberta Bongiorno, Maria Teresa Majorini, Valeria Figa', Davide Pernici et autres

0 citationsbioRxiv (Cold Spring Harbor Laboratory)

Accès ouvert 2026 article

Pan-cancer multi-omic integration of Trop2 reveals biological determinants and translational implications for ADC therapy

Giulia Notini, Barbara Galbardi, Giulia Viale, Matteo M. Naldini et autres

1 citationnpj Precision Oncology

2026 article

The promyelocytic leukemia PML protein coordinates immune evasion in triple-negative breast cancer via independent and converging mechanisms

Martina Uggé, Cristina Fracassi, Anna Sofia Tascini, Valentina Giansanti et autres

0 citationsCell Death and Differentiation

2026 conference-abstract

Abstract 6752: Mapping the spatial organisation of B cells and immune signalling in TNBC to characterise response to immunotherapy

Lubna Ahmad, Xiao Qian Wang, Neus Masqué-Soler, Ellen Schrader et autres

0 citationsCancer Research

2026 conference-abstract

Abstract PS2-09-09: Early on-treatment PD-L1 expression and stromal tumor infiltrating lymphocytes (sTILs) refine the prediction of EFS in the NeoTRIP trial

Matteo Dugo, G. Viale, H. Chiun-Sheng, D. Egle et autres

0 citationsClinical Cancer Research

Accès ouvert 2025 article

Mixed Molecular Subtypes Coexist in Estrogen Receptor Heterogeneous Primary Breast Cancers

Julia Foldi, Kaitlyn Xiong, Matthew Liu, Charles T. Robbins et autres

0 citationsJCO Precision Oncology

Accès ouvert 2025 article

Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancer

Justin M. Balko, Luca Licata, Xiao Qian Wang, Matteo Dugo et autres

1 citationnpj Breast Cancer

Accès ouvert 2025 erratum

Correction: CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer

Lorenzo Castagnoli, Alma Franceschini, Valeria Cancila, Matteo Dugo et autres

1 citationJournal of Experimental & Clinical Cancer Research

2025 conference-abstract

Analysis of event-free survival (EFS) of stromal tumor infiltrating lymphocytes (sTILs), PD-L1 expression, and their early dynamics in the NeoTRIP trial.

Giampaolo Bianchini, Giulia Viale, Matteo Dugo, Chiun‐Sheng Huang et autres

0 citationsJournal of Clinical Oncology

Accès ouvert 2025 article

72P Predictive value of spatially-derived archetypes and tertiary lymphoid structure signature in the NeoTRIP trial

Matteo Dugo, David Venet, Chiun‐Sheng Huang, Xiaoyang Wang et autres

0 citationsESMO Open

2025 conference-abstract

Abstract 1712: CD36 enrichment in HER2+ mesenchymal stem cells potentiates therapy refractoriness in HER2+ breast cancer

Lorenzo Castagnoli, Valeria Cancila, Martina Bigliardi, Matteo Dugo et autres

0 citationsCancer Research

Accès ouvert 2025 erratum

Correction: Exosome-mediated delivery of miR-9 induces cancer-associated fibroblast-like properties in human breast fibroblasts

Sara Baroni, Sandra Romero‐Córdoba, Ilaria Plantamura, Matteo Dugo et autres

1 citationCell Death and Disease

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Métadonnées interrogées à la demande auprès de OpenAlex (CC0). Sources et limites.